신경종양 정밀의학 연구실

The Choi Lab aims to uncover the molecular rationale underlying therapeutic refractoriness in brain tumors, particularly gliomas. Despite remarkable advances in cancer research, gliomas remain among the most aggressive and treatment-resistant malignancies. Our mission is to bridge molecular understanding with clinical relevance—integrating multi-omics data, phenotypic observations, and clinical insights to reveal the biological principles that govern tumor behavior and therapy response. In the long term, our goal is to translate these discoveries into actionable precision medicine strategies that not only improve the outcomes of patients with malignant brain tumors but also inform broader approaches to therapy resistance in other refractory cancers. Through data-driven discovery and interdisciplinary collaboration, we seek to transform the way we understand, predict, and ultimately overcome treatment failure in neuro-oncology and beyond. Brain tumors pose unique therapeutic challenges due to the complex and delicate nature of the brain. Among them, gliomas—the most common primary malignant brain tumors—remain among the most devastating cancers, with limited treatment options despite significant advances in medicine. Because of their profound heterogeneity, targeted therapies often fail to eradicate all tumor subpopulations. In particular, glioblastoma (GBM), the most aggressive form of glioma, almost invariably recurs due to its infiltrative nature and adaptive cellular ecosystem. To overcome these challenges, our research focuses on two complementary directions that together aim to provide more durable and comprehensive therapeutic strategies for malignant brain tumors. We aim to develop individualized therapeutic strategies that target predominant tumor clones based o